Flexible research opportunities with existing and upcoming global registries

Computer screen with dashboard / graphs and phone with app login screen

Our innovative multi-client syndicated registries support case-by-case real-world evidence generation needs while improving study flexibility and speed for all stakeholders through harmonized governance, design, and data collection.

Develop research initiatives using an existing registry dataset

Act as a pre-launch registry Founder and influence decision-making on study design and development


Subscribe for access to an existing dataset

  • Custom research options can bridge to customer evidence plans ​
  • Ability to use a consent-to-contact about future research opt-in registry cohort to accelerate recruitment into clinical trial​s
  • Customized safety reporting for marketed products
  • Opportunity for registry expansion (e.g., geography, paediatric, etc.)
  • Subscribers enjoy cost savings via shared funding approach, comparing favorably to costly independent registries that will compete for stakeholders​
  • Comprehensive and real-world evidence solution to support multiple stakeholders (Medical Affairs, HEOR, Market Access and Commercial, Safety and Regulatory)​
  • Our experience shows that PAGs and KOLs prefer collaborative, even-handed modus operandi with pharmas​
  • Vitaccess and PAG+KOL synergies leverage a wealth of experience in running registries and uniting the research, patient, and HCP communities
  • Linkage of patient- and HCP-reported data with clinical data from medical records.
  • Repeated data collection and testing and collection of overlapping information can be invaluable for continuous learning, evidence sharing, and ultimate acceleration of research and therapy development
  • Dashboards enable near real-time visualization of aggregated anonymous data for patients, HCPs, and pharma
  • Having a network of clinical centers to serve as study sites for multiple studies is more efficient for researchers, sites, and patients
  • Transitioning from pre- to post-approval subscription maximizes recruitment of patients at initiation once subscriber treatment achieves market access
yellow divider line

Explore a range of pre- and post-authorization use cases to meet your evidence generation needs

MyRealWorld MG

Since May 2023, MyRealWorld MG is being run under a syndicated framework.

Via this framework, Vitaccess is providing the opportunity for novel research initiatives using the anonymized study dataset, including extended commercial subscriptions.

For more information on the MyRealWorld MG study or research opportunities using the study dataset, please contact us at or use the contact form below.

MyRealWorld MG app screen log in page
yellow divider line

Discover more about opportunities with our existing or upcoming syndicated registries

get in touch today

Real data. Patient progress.

Skip to content